HIGHLIGHT
Actranex

Actranex

tranexamic acid

Manufacturer:

Gufic Biosciences

Distributor:

Cathay Drug
Concise Prescribing Info
Contents
Tranexamic acid
Indications/Uses
Treatment & prophylaxis of haemorrhage associated w/ excessive fibrinolysis. Prophylaxis of hereditary angioedema.
Dosage/Direction for Use
Short term use in haemorrhage 0.5-1 g (or 10 mg/kg) tid by slow IV inj or 25-50 mg/kg daily by continuous infusion. Childn 10 mg/kg bid or tid.
Contraindications
Hypersensitivity. Acute venous or arterial thrombosis, fibrinolytic conditions following consumption coagulopathy except patients w/ predominant activation of fibrinolytic system w/ acute severe bleeding, severe renal impairment (risk of accumulation), history of convulsions, intrathecal & intraventricular inj, intracerebral application (risk of cerebral oedema & convulsions).
Special Precautions
Convulsion, visual disturbances, haematuria from upper urinary tract, history of thromboembolic diseases or those w/ increased incidence of thromboembolic events in the family history, patients w/ disseminated intravascular coagulation. Administer w/ care in patients receiving OCs. Not recommended during 1st trimester of pregnancy & breastfeeding.
Adverse Reactions
GI disturbances, hypotension, thrombotic complications, transient disturbances of colour vision, hypersensitivity skin reactions.
MIMS Class
Haemostatics
ATC Classification
B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Presentation/Packing
Form
Actranex soln for inj 100 mg/mL
Packing/Price
5 mL x 5 × 1's (P750.4/box, P150.08/ampoule)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in